GE
GERN.US Geron Corporation
- Market cap
- USD 623M
- P/E
- -
- P/B
- 2.82x
- ROE
- -11.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GERN.US undervalued?
Graham numberThe Graham number of Geron Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Geron Corporation fundamental analysis
No fundamental analysis for Geron Corporation yet.
Geron Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment …
Full company profileGeron Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Geron Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.16M | 1.07M | 1.07M | 460K | 253K | 1.39M | 596K | 237K | 77.0M | 184M | 226M |
| Gross Profit | -8.53M | -7.37M | -11.7M | 460K | -49.8M | 1.39M | 596K | 237K | 75.7M | 179M | 203M |
| Operating Income | -30.6M | -29.3M | -31.1M | -72.5M | -76.9M | -114M | -139M | -194M | -174M | -53.8M | -9.34M |
| EBITDA | -30.6M | -29.2M | -27.0M | -71.7M | -76.0M | -112M | -134M | -175M | -155M | -51.9M | 759K |
| Net Income | -29.5M | -27.9M | -27.0M | -63.6M | -75.6M | -116M | -142M | -184M | -175M | -85.8M | -25.3M |
| EPS | -0.19 | -0.18 | -0.15 | -0.33 | -0.28 | -0.35 | -0.37 | -0.32 | -0.27 | -0.13 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 130M | 110M | 185M | 166M | 271M | 226M | 191M | 394M | 594M | 571M | 527M |
| Total Liabilities | 7.87M | 6.52M | 7.55M | 30.4M | 59.8M | 99.6M | 111M | 146M | 313M | 345M | 300M |
| Shareholders' Equity | 122M | 104M | 178M | 135M | 211M | 126M | 80.0M | 248M | 280M | 226M | 227M |
| Cash & Short-term Investments | 115M | 95.0M | 164M | 139M | 196M | 184M | 173M | 334M | 407M | 360M | 288M |
| Total Debt | - | - | - | 2.55M | 29.7M | 55.0M | 55.8M | 85.9M | 122M | 252M | 121M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.4M | -20.6M | -21.0M | -43.8M | -66.7M | -95.6M | -127M | -168M | -219M | -111M | -91.3M |
| Capital Expenditure | 57.0K | 16.0K | 16.0K | 413K | 401K | 207K | 431K | 830K | 680K | 49.0K | 839K |
| Free Cash Flow | -18.4M | -20.6M | -21.0M | -44.2M | -67.1M | -95.8M | -128M | -169M | -219M | -111M | -92.1M |
| Ratios | |||||||||||
| ROE | -24.1% | -26.9% | -15.2% | -47.0% | -35.8% | -91.8% | -177.4% | -74.3% | -62.3% | -38.0% | -11.2% |
| ROA | -22.7% | -25.3% | -14.6% | -38.4% | -27.9% | -51.4% | -74.5% | -46.7% | -29.4% | -15.0% | -4.8% |
| Net Profit Margin | -479.3% | -2,621.2% | -2,534.4% | -13,815.4% | -29,888.1% | -8,335.4% | -23,808.9% | -77,690.7% | -226.7% | -46.7% | -11.2% |
| Debt to Equity | - | - | - | 0.02x | 0.14x | 0.44x | 0.70x | 0.35x | 0.43x | 1.11x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Geron Corporation dividends
Geron Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1058:1000 on Jul 22, 2014.
Who owns Geron Corporation
- Insiders 0.08%
- Institutions 76.84%
- Public & others 23.08%
- Shares outstanding 644M
- Free float 558M
Top funds holding GERN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 20.4M | 3.17% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 19.4M | 3.01% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 14.0M | 2.17% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 13.0M | 2.02% | 0.00% | Sep 2026 |
| ClearBridge Small Cap Growth A | 6.32M | 0.98% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 6.12M | 0.95% | +0.34% | Aug 2026 |
| Belfius Equities Cure C Cap | 5.59M | 0.87% | +42.53% | Apr 2026 |
| Fidelity Select Biotechnology | 5.45M | 0.85% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 5.30M | 0.82% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 4.95M | 0.77% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 3.25M | 0.50% | +1.02% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 3.10M | 0.48% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 2.74M | 0.42% | +2.32% | Sep 2026 |
| Virtus Biotech ETF | 1.52M | 0.24% | +4.01% | Oct 2026 |
| LVIP FranklinTempletonMltFctSMIDCapEqStd | 1.47M | 0.23% | +149.77% | Sep 2026 |
| Vanguard Health Care ETF | 1.46M | 0.23% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 1.36M | 0.21% | -0.25% | Sep 2026 |
| ClearBridge Variable Small Cap Growth I | 1.34M | 0.21% | 0.00% | Sep 2026 |
| EdRF Healthcare A EUR | 1.20M | 0.19% | -0.09% | Sep 2026 |
| Vanguard VIF Small Co Gr | 1.11M | 0.17% | 0.00% | Sep 2026 |
Top institutions holding GERN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 49.1M | 7.62% | +3.80% | Jun 2026 |
| RA Capital Management, LLC | 42.8M | 6.65% | -32.87% | Jun 2026 |
| Soleus Capital Management, L.P. | 42.8M | 6.64% | +3.13% | Jun 2026 |
| State Street Corp | 35.9M | 5.57% | +17.57% | Jun 2026 |
| Citadel Advisors Llc | 29.0M | 4.51% | +34.59% | Jun 2026 |
| Vanguard Capital Management, LLC | 27.3M | 4.23% | +2.18% | Jun 2026 |
| Nantahala Capital Management, LLC | 24.5M | 3.80% | +117.82% | Jun 2026 |
| ClearBridge Advisors, LLC | 19.6M | 3.05% | +0.15% | Jun 2026 |
| Eversept Partners, LP | 18.7M | 2.91% | -0.62% | Jun 2026 |
| The Goldman Sachs Group Inc | 16.6M | 2.58% | +48.82% | Jun 2026 |
| Geode Capital Management, LLC | 14.6M | 2.26% | +6.47% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 12.9M | 2.01% | +2.21% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 10.8M | 1.68% | +131.59% | Jun 2026 |
| Vivo Capital, LLC | 8.67M | 1.35% | 0.00% | Jun 2026 |
| Millennium Management LLC | 8.11M | 1.26% | +10.80% | Jun 2026 |
| Kynam Capital Management, LP | 6.84M | 1.06% | 0.00% | Jun 2026 |
| Candriam Luxembourg S.C.A. | 5.59M | 0.87% | +42.53% | Jun 2026 |
| FMR Inc | 5.50M | 0.85% | -16.59% | Jun 2026 |
| Pale Fire Capital SE | 5.31M | 0.82% | +8.57% | Jun 2026 |
| Northern Trust Corp | 5.03M | 0.78% | +3.50% | Jun 2026 |
Geron Corporation company profile
- Company name
- Geron Corporation
- Ticker
- GERN.US
- Exchange
- USA Stocks
- Listed since
- Jun 30, 1996
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 258
- Fiscal year end
- December
- Address
- 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404
- Phone
- 650 473 7700
- Website
- geron.com
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation management
10- Mr. Harout SemerjianCEO, President & Director · born 1970
- Ms. Michelle J. RobertsonEVP, CFO, Treasurer and Principal Financial & Accounting Officer · born 1967
- Dr. Joseph Emile Eid M.D.Executive VP of Research & Development and Chief Medical Officer · born 1967
- Mr. Ahmed ElNawawiExecutive VP & Chief Commercial Officer · born 1981
- Mr. Shanthakumar TyavanagimattSenior VP & Chief Technical Officer
- Ms. Dawn Schottlandt CFASenior Vice President of Investor Relations & Corporate Affairs
- Mr. Timothy Williams J.D.Executive VP, Chief Legal Officer & Corporate Secretary · born 1977
- Ms. Aron FeingoldVice President of Investor Relations & Corporate Communications
- Ms. Shannon T. OdamExecutive VP & Chief People Officer · born 1975
- Mr. Bryan RidgellSenior VP of Portfolio & Project Management and Chief of Staff